# AVENGER 500 (NCT03504423)

> Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

No report yet. It can be ordered.

- Drugs tested: devimistat (CPI-613)
- Indication: metastatic adenocarcinoma of the pancreas

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03504423
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Cornerstone Pharmaceuticals
- Conditions: Pancreatic Cancer Metastatic
- Interventions: CPI 613, mFolfirinox; Folfirinox
- Enrollment: 528
- Primary outcome: Overall Survival (OS)

## Indexed commentary on AVENGER 500 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 10
- YouTube: 1

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=avenger-500-nct03504423

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03504423", "email": "<work email>"}; the inbox owner confirms by the emailed link.